1-6 of 6
Nicolas Isambert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Free
Antoine Hollebecque, Stefania Salvagni, Ruth Plummer, Nicolas Isambert, Patricia Niccoli, Jaume Capdevila, Giuseppe Curigliano, Victor Moreno, Patricia Martin-Romano, Eric Baudin, Marina Arias, Sheila Mora, Juan de Alvaro, Jorge Di Martino, Josep L. Parra-Palau, Tania Sánchez-Pérez, Ida Aronchik, Ellen H. Filvaroff, Manisha Lamba, Zariana Nikolova, Johann S. de Bono
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 438–446.
https://doi.org/10.1158/1078-0432.CCR-20-2380
Published: 19 January 2021
View articletitled, Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Open the PDF for Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Free
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, François Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, François Le Loarer, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4859.
https://doi.org/10.1158/1078-0432.CCR-19-1599
Published: 01 August 2019
View articletitled, Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Open the PDF for Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study in another window
Journal Articles

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Available to Purchase
Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, François Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, François Le Loarer, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4611–4615.
https://doi.org/10.1158/1078-0432.CCR-18-3127
Published: 01 August 2019
View articletitled, Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Open the PDF for Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study in another window
Includes: Supplementary data
Journal Articles

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Available to Purchase
Daniel D. Von Hoff, Drew W. Rasco, Elisabeth I. Heath, Pamela N. Munster, Jan H.M. Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert O'Neil, Ron H.J. Mathijssen, Jose A. Lopez-Martin, W. Jeff Edenfield, Miguel Martin, Patricia M. LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4072–4080.
https://doi.org/10.1158/1078-0432.CCR-17-3716
Published: 04 September 2018
View articletitled, Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Open the PDF for Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics

Available to Purchase
Antoine Italiano, Pauline Lagarde, Céline Brulard, Philippe Terrier, Marick Laë, Bernard Marques, Dominique Ranchere-Vince, Jean-Jacques Michels, Martine Trassard, Angela Cioffi, Sophie Piperno-Neumann, Christine Chevreau, Jean-Yves Blay, Corinne Delcambre, Nicolas Isambert, Nicolas Penel, Jacques-Olivier Bay, Sylvie Bonvalot, Axel Le Cesne, Jean-Michel Coindre, Frédéric Chibon
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1190–1196.
https://doi.org/10.1158/1078-0432.CCR-12-2970
Published: 03 March 2013
View articletitled, Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics
Open the PDF for Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors

Available to Purchase
Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, Pierre Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, Samira Ziti-Ljajic, Veronique Trillet-Lenoir
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1743–1750.
https://doi.org/10.1158/1078-0432.CCR-11-1918
Published: 14 March 2012
View articletitled, Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data